Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series

Firas El Chaer, Nobuyoshi Mori, Dimpy Shah, Nora Oliver, Emily Wang, Anna Jan, Vi Doan, Frank Tverdek, Jean Tayar, Ella Ariza-Heredia, Roy F. Chemaly

Resultado de la investigación: Articlerevisión exhaustiva

14 Citas (Scopus)

Resumen

Cytomegalovirus (CMV) reactivation is a clinically significant complication in hematopoietic stem cell transplant (HCT) recipients. Alternative therapy for multidrug-resistant CMV is limited and often fails. Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking. In this report, we describe 3 HCT recipients with multi-drug resistant CMV infections who received leflunomide as adjuvant and salvage therapy. The therapeutic effect of leflunomide as an anti-CMV agent based on virologic responses and therapeutic drug monitoring were evaluated.

Idioma originalEnglish (US)
Páginas (desde-hasta)91-96
Número de páginas6
PublicaciónAntiviral Research
Volumen135
DOI
EstadoPublished - nov. 1 2016
Publicado de forma externa

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Huella

Profundice en los temas de investigación de 'Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series'. En conjunto forman una huella única.

Citar esto